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were analyzed. Patients initially received corticosteroids 
but were steroid-dependent and/or partially refractory. 
One patient was administered infliximab but was refrac-
tory. The median time from onset of enterocolitis to start 
of vedolizumab therapy was 79 days. Following vedoli-
zumab therapy, all patients but one experienced steroid-free 
enterocolitis remission, with normalized fecal calprotectin. 
This was achieved after a median of 56 days from vedoli-
zumab start, without any vedolizumab-related side-effects 
noted. The patient in whom vedolizumab was not success-
ful, due to active ulcerative colitis, received vedolizumab 
prophylactically. This is the first case series to suggest that 
vedolizumab is an effective and well-tolerated therapeutic 
for steroid-dependent or partially refractory ICPI-induced 
enterocolitis. A larger prospective study to evaluate vedoli-
zumab in this indication is warranted.
Keywords Ipilimumab · Nivolumab · Melanoma · 
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Abbreviations
B  Blood
CRP  C-reactive protein
CTLA-4  Cytotoxic T-lymphocyte antigen-4
ECOG  Eastern cooperative oncology group
ELISA  Enzyme-linked immunosorbent assay
F  Fecal
IBD  Inflammatory bowel diseases
ICPI  Immune checkpoint inhibitor
irAE  Immune-related adverse event
MAdCAM-1  Mucosal addressin cellular adhesion 
molecule-1
NLR  Neutrophil/lymphocyte ratio
P  Plasma
Abstract Immune checkpoint inhibitors (ICPI), such 
as ipilimumab [anti-cytotoxic T-lymphocyte antigen-4 
(CTLA-4) antibody] and nivolumab or pembrolizumab 
[anti-programmed cell death protein-1 (PD-1) antibodies], 
improve survival in several cancer types. Since inhibi-
tion of CTLA-4 or PD-1 leads to non-selective activation 
of the immune system, immune-related adverse events 
(irAEs) are frequent. Enterocolitis is a common irAE, cur-
rently managed with corticosteroids and, if necessary, 
anti-tumor necrosis factor-α therapy. Such a regimen car-
ries a risk of serious side-effects including infections, and 
may potentially imply impaired antitumor effects. Vedoli-
zumab is an anti-integrin α4β7 antibody with gut-specific 
immunosuppressive effects, approved for Crohn’s disease 
and ulcerative colitis. We report a case series of seven 
patients with metastatic melanoma or lung cancer, treated 
with vedolizumab off-label for ipilimumab- or nivolumab-
induced enterocolitis, from June 2014 through October 
2016. Clinical, laboratory, endoscopic, and histologic data 
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PD-1  Programmed cell death protein-1
PML  Progressive multifocal 
leukoencephalopathy
SES-CD  Simple endoscopic score for Crohn’s 
disease
TNF  Tumor necrosis factor
UCEIS  Ulcerative colitis endoscopic index of 
severity
Introduction
Immune checkpoint inhibitors (ICPIs) have greatly 
improved possibilities for treatment in oncology. The 
physiological role of immune checkpoints, such as cyto-
toxic T-lymphocyte antigen-4 (CTLA-4) and programmed 
cell death protein-1 (PD-1) which are expressed primarily 
on T cells, is to regulate the degree of T cell activation, 
to prevent exaggerated immune responses or autoimmun-
ity [1]. CTLA-4 is thought to control initial T cell activa-
tion and proliferation in lymph nodes early in an immune 
response. In contrast, PD-1 regulates T cell activity later 
in an immune response, at the effector site, i.e. the tumor 
[1]. Antibodies blocking CTLA-4 (ipilimumab) or PD-1 
(nivolumab and pembrolizumab) thus augment the immu-
nological response to tumors through related but distinct 
mechanisms. Furthermore, it is thought that antibodies 
to CTLA-4 induce depletion of regulatory T cells which 
express CTLA-4 [1, 2]. These new drugs have shown sig-
nificant survival benefits in advanced melanoma, non-small 
cell lung cancer, renal cancer, and squamous head and neck 
cancer, and their efficacy is being investigated in several 
other cancers [1, 3].
ICPIs expand and/or activate not only tumor-specific 
T cells but also numerous other T cell clones. This may 
break down peripheral self-tolerance and cause immune-
related adverse events (irAEs). ICPIs have been shown to 
be associated with a number of irAEs, such as enterocol-
itis, hepatitis, rash, vitiligo, and hypophysitis [4, 5]. Most 
irAEs are manageable but they can occasionally be very 
severe and even fatal as in cases with enterocolitis that 
leads to intestinal perforation [6–8]. Severe or life-threat-
ening irAEs (grade 3–4) are more common with CTLA-4 
blockers (reported rates of 20–27%) than with PD-1 block-
ers (13–16%), whereas with combination treatment the rate 
rises to around 50% [3, 8]. The most common grade 3–4 
irAEs with all of the various ICPI regimes are gastrointesti-
nal (i.e. diarrhea, enterocolitis, and hepatitis) [4, 5].
Currently, irAEs are managed in accordance with 
algorithms that are broadly used but not evidence based 
[9]. Mild (grade 1) diarrhea/enterocolitis can be man-
aged with symptomatic therapy, but in moderate and 
severe cases (grade 2–3), corticosteroids are used [4, 5]. 
If corticosteroids are not sufficient, i.e. lack of response to 
high-dose corticosteroids (2  mg/kg methylprednisolone) 
within days, more potent immunosuppressive agents such 
as infliximab [anti-tumor necrosis factor (TNF) α anti-
body], mycophenylate mofetil, or calcineurin inhibitors are 
recommended [5].
The level of inflammation in the gut can be measured in 
several ways. The traditional way is to quantify symptoms, 
primarily the number of bowel movements per day. This 
parameter is used to grade ICPI-induced diarrhea. A draw-
back with using symptoms for quantifying inflammation 
is that they are indirect and subjective in character. Colo-
noscopy is the gold standard but is cumbersome to perform 
repeatedly. An even more stringent measure is the histology 
of the gut mucosa. Plasma CRP and albumin are used but 
may be affected by other systemic inflammatory processes. 
A relatively new measure of gut inflammation, that has 
high sensitivity and specificity, is the fecal (F) concentra-
tion of calprotectin. Calprotectin is a calcium-binding pro-
tein derived primarily from neutrophils and activated mac-
rophages [10]. Levels of F-calprotectin have been shown to 
correlate closely with gastrointestinal inflammation [11].
Blood lymphocyte counts have shown a positive corre-
lation, and the blood neutrophil/lymphocyte ratio (NLR) a 
negative correlation, with overall survival in several solid 
tumor diseases, both before and after the onset of ICPI 
therapy, and both with and without corticosteroid therapy 
taken into account [12, 13]. Corticosteroids are known to 
induce apoptosis in lymphocytes but not neutrophils [14] 
and to induce demargination of neutrophils from the endo-
vascular lining. Similarly, infliximab functions by inducing 
apoptosis of activated T-lymphocytes through transmem-
brane TNFα, in addition to inhibiting soluble TNFα [15].
Vedolizumab is a humanized monoclonal IgG1 antibody 
against α4β7 integrin, approved for treatment of Crohn’s 
disease and ulcerative colitis, collectively called inflam-
matory bowel diseases (IBD) [16, 17]. α4β7 integrin is 
expressed primarily on a subset of  CD4+ T cells and medi-
ates homing of these cells specifically to the gut [18, 19]. 
The counter-receptor of α4β7, mucosal addressin cellular 
adhesion molecule 1 (MAdCAM-1), is expressed selec-
tively on venule endothelial cells of the gut but not in other 
organs [18, 20]. Blocking of α4β7 integrin thus results in 
a gut-specific immunosuppression, while the immunity in 
extraintestinal tissues remains intact [20]. In addition, ved-
olizumab is specific for the dimer α4β7 and does not bind 
to other integrins that comprise the α4 or β7 subunit, such 
as α4β1 which is important for the homing of lympho-
cytes to a number of organs [19]. The gut-specific effect 
of vedolizumab is further illustrated by the fact that there 
have not been any reports of progressive multifocal leu-
koencephalopathy (PML) with vedolizumab, in contrast to 
another integrin-inhibitor, natalizumab, which targets α4β1 
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in addition to α4β7, and thus inhibits lymphocyte function 
systemically [21]. It is well recognized that vedolizumab 
has a gradual onset of therapeutic effect [22]. This may 
be explained by the mode-of-action which is inhibition of 
recruitment of new lymphocytes to the gut mucosa, with 
less effect on the cells already present in the inflamed gut 
tissue [20].
Here, we report on seven patients with ICPI-induced 
enterocolitis, which were either corticosteroid-dependent 
and/or partially refractory, managed successfully with ved-
olizumab infusions.
Methods
Seven patients who had received immunotherapy with 
either ipilimumab or nivolumab against advanced mela-
noma (n = 6) or non-small cell lung cancer (n = 1) between 
January 2014 and July 2015 at Skane University Hospital, 
received subsequent treatment with vedolizumab due to 
IPCI-induced enterocolitis (here defined as inflammation 
primarily of the colon and distal ileum with or without 
confirmed inflammation in more proximal segments). The 
first of these patients was started on vedolizumab therapy 
in June 2014 and the last in June 2016. The therapy deci-
sions were clinically based and taken by a multidiscipli-
nary team comprising gastroenterologists and oncologists. 
The patients were, retrospectively, identified and enrolled 
for review and analysis of medical records. The study was 
approved by the regional ethics committee in Lund, Swe-
den (reference No. 2016/624). No patient consent was 
required as this was a retrospective study. The study was 
performed in accordance with the ethical standards of the 
1964 Helsinki declaration and its later amendments.
All laboratory blood and fecal tests were taken as part 
of clinical routine. F-calprotectin was measured using a 
commercially available enzyme-linked immunosorbent 
assay (ELISA) (Calpro AS). The lower limit of the ELISA 
was 30  mg/kg; values below this cut-off were estimated 
as 15  mg/kg. F-calprotectin levels <50  mg/kg are normal 
according to the manufacturer, but studies in IBD have sug-
gested 100 mg/kg to be a more adequate cut-off level [23].
The degree of diarrhea was graded 1 to 5 in accordance 
with the Common Terminology Criteria for Adverse Events 
version 4.0 which grades the increase in number of stools 
per day above the baseline value [24]: Grade 1, increase of 
<4 stools; grade 2, 4–6 stools; grade 3, ≥7 stools; grade 
4, diarrhea with life-threatening consequences; grade 5, 
death. Films and pictures from the ileocolonoscopic exami-
nations recorded for clinical purposes, were categorized 
blindly by an experienced endoscopist into normal, mild, 
moderate, or severe inflammation, based on global assess-
ment of the most inflamed segment with regards to several 
parameters including erythema, vascular pattern, granu-
larity, bleeding, and ulceration. In addition, the ileocolo-
noscopic examinations were scored using the Ulcerative 
Colitis Endoscopic Index of Severity (UCEIS) [25] and the 
Simple Endoscopic Score for Crohn’s Disease (SES-CD) 
[26], respectively. These scores were used since a specific 
endoscopic index for immune-therapy associated entero-
colitis does not exist, as yet. The score range for a single 
intestinal segment is 0–8 for UCEIS and 0–12 for SES-CD, 
and 0–20 for the combination of these. Thresholds defining 
remission, mild, moderate, and severe disease have yet to 
be established. However, for UCEIS, it has been suggested 
that a score of 0–1 represents remission and 7–8 represents 
severe disease in the context of ulcerative colitis, whereas 
the cut-off separating mild from moderate disease remains 
unclear [27]. Colonic mucosal histopathology was catego-
rized into normal, mild, moderate, or severe inflammation 
based on global assessment of several parameters including 
acute and chronic inflammatory infiltration of lamina pro-
pria and the epithelium, and architectural disorder.
Performance status was assessed in accordance with the 
Eastern Cooperative Oncology Group (ECOG) scale rang-
ing from 0 to 5 [28]. Statistical analysis was performed 




Five patients diagnosed with metastatic melanoma (stage 
IV) and one with melanoma stage IIIc were treated with 
ipilimumab. One patient with non-small cell lung cancer 
stage IV was treated with nivolumab. Patient characteristics 
are summarized in Table  1. At initiation of ICPI therapy, 
patient age ranged from 40 to 71 years with a median of 55 
years. The male to female ratio was 4:3. Performance status 
according to the ECOG scale was 0 for three patients and 1 
for four patients at initiation of therapy.
Two patients had a history of inflammatory bowel dis-
ease. Patient No. 3 had a history of ulcerative colitis that 
increased in activity after treatment with pembrolizumab. 
Before this patient was switched to ipilimumab because of 
tumor progression, she was started on prophylactic ved-
olizumab treatment. Patient No. 7 had undergone a right 
hemicolectomy due to Crohn’s disease in adolescence, 
which led to sustained inflammatory remission, and showed 
no signs of inflammatory bowel disease when nivolumab 
therapy was started. This patient had previously also been 
diagnosed with atrial fibrillation, pulmonary embolism, 
sarcoidosis and chronic obstructive pulmonary disease. 
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Patients No. 2 and No. 5 had a history of prostate and cer-
vical cancer, respectively.
Cancer therapy
Ipilimumab or nivolumab were dosed at 3 mg/kg of body 
weight with an interval of 3 weeks for ipilimumab and 2 
weeks for nivolumab, in all patients except for patient No. 6 
who was given 10 mg/kg body weight of ipilimumab every 
3 weeks (Table 1). Between infusions 1 and 2, patient No. 
5 received radiation therapy against axillary lymph nodes 
with 25  Gy in 5 fractions. Four patients had previously 
received chemotherapy and/or another type of immunother-
apy (Table 1). The number of infusions given before onset 
of enterocolitis symptoms ranged from 2 to 4 for patients 
receiving ipilimumab, whereas the patient on nivolumab 
therapy received 18 doses prior to symptom development 
(Table  1). ICPI therapy was discontinued in all patients 
upon development of grade 3 enterocolitis with grade 2–3 
diarrhea, and the total number of infusions hence equals the 
number of infusions given before symptom onset.
Diagnosis, management, and evaluation 
of ICPI-induced enterocolitis
The median time that elapsed from the first dose of ipili-
mumab to onset of enterocolitis symptoms was 65 days 
(range 38–88 days) (Table  2). The median time from the 
last dose to development of symptoms was 19 days (range 
9–27 days) (Table  2). Patient No. 7 who received 18 
nivolumab infusions did not develop enterocolitis until 292 
days after therapy was commenced. Two patients presented 
with grade 2 diarrhea, and five patients with grade 3 diar-
rhea (Table 2). Patient No. 5 developed additional immune-
related adverse events (irAEs) in the form of rash and iritis, 
but in the other patients diarrhea/enterocolitis were the only 
irAEs requiring treatment. Bacterial cause for diarrhea was 
ruled out by means of stool cultures and Clostridium diffi-
cile toxin tests. At diagnosis, all patients were examined by 
computed tomography scanning. Large and/or small bowel 
wall thickening was present in five cases, and in two cases 
the scans was considered inconclusive.
The patients were initially treated with corticosteroids in 
accordance with international recommendations for treat-
ment of IPCI-induced enterocolitis [4, 5], including intra-
venous administration of methylprednisolone dosed up to 
2 mg/kg body weight. The enterocolitis that these patients 
displayed was either partially steroid-refractory (i.e. partial 
but not complete response) and/or steroid-dependent (i.e. 
at adequate tapering of high-dose corticosteroids, patients 
exhibited increased signs of enterocolitis).
Prior to starting vedolizumab therapy, all patients under-
went ileocolonoscopy. Endoscopic inflammatory signs were 
scored in accordance with the UCEIS and SES-CD indexes 
and an integrated global inflammation categorization was 
performed. Two patients displayed mild endoscopic inflam-
mation and five displayed moderate inflammation, accord-
ing to the global endoscopic assessment (Table  2). The 
mean UCEIS, SES-CD, and combined scores for patients 
with mild or moderate endoscopic findings are shown in 
Fig.  1a. Histopathologic evaluation of colonic mucosal 
biopsies showed mild inflammation in three cases, moder-
ate inflammation in two cases, and severe inflammation in 
two cases (Table 2). The combined endoscopic scores cor-
responded well to the histopathologic findings as shown in 
Fig. 1b.
Vedolizumab treatment for ICPI-induced enterocolitis
When treated for their ICPI-induced diarrhea/enterocol-
itis, patients No. 1, 4, 6, and 7 responded to high-dose 
corticosteroids but were considered steroid-dependent 
as they relapsed when therapy was tapered in accordance 
with international recommendations (i.e. tapering sched-
uled over 4–8 weeks). Patients No. 2, 3, and 5 responded 
only partially to high-dose corticosteroids and were thus 
considered partially steroid-refractory (Table  2). Inad-
equate inflammatory control on corticosteroid therapy 
despite optimized dosing and repeated retapering attempts, 
prompted the use of vedolizumab. The median time from 
onset of enterocolitis to start of vedolizumab was 79 days 
(range 57–86) (Table  2). Vedolizumab was administered 
with infusions of 300 mg at time-points 0, 2, and 6 weeks 
or until clinical and laboratory regression was observed 
(Table  2). This corresponds to the induction treatment 
regimen recommended for Crohn’s disease and ulcerative 
colitis. Patient No. 7 initially received infliximab therapy 
but since this was unsuccessful, vedolizumab was admin-
istered. At the start of vedolizumab treatment, patient No. 
1, 2, 4, 5, and 6 displayed grade 1, and patient No. 7 grade 
3 diarrhea. In addition, patient No. 6 and 7 had abdominal 
pain. The number of vedolizumab infusions given was 2 to 
4; at the time of the first infusion, the daily dose of pred-
nisolone ranged from 20 to 160 mg with a mean of 78 mg 
(Table 2). Prednisolone could then be successfully tapered 
in all of the patients except in patient No. 3. The median 
time from start of vedolizumab treatment to steroid-free 
remission from enterocolitis symptoms was 56 days (range 
52–92 days). No side effects related to vedolizumab treat-
ment were observed (Table 2).
Patient No. 3 had mildly active ulcerative colitis before 
initiation of ipilimumab therapy and was given vedoli-
zumab for prophylactic purpose 1 week prior to initiation 
of ipilimumab infusions to avoid potential aggravation 
of the underlying colitis disease, as opposed to induction 
therapy against ICPI-induced enterocolitis. Unfortunately, 
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diarrheal symptoms increased markedly after the fourth 
ipilimumab dose and thus the desired protective effect from 
vedolizumab was not achieved.
Routine laboratory tests, including plasma (P) C-reactive 
protein (CRP), P-albumin, blood (B) neutrophils, B-lym-
phocytes, and F-calprotectin, were taken in all patients 
before, during, and after the periods when ICPI therapy and 
vedolizumab, respectively, were administered (Figs.  2, 3). 
Patient No. 3 was excluded from the analyses presented in 
Figs. 2 and 3 since vedolizumab in this case was given pro-
phylactically (see above).
Median P-CRP and F-calprotectin were increased at 
the onset of diarrhea to 23.5 mg/L (range 1.8–154.0) and 
915  mg/kg (range 228–1799), respectively, and decreased 
as a result of treatment with corticosteroids to 14.0 mg/L 
(range 2.0–28.0) and 382  mg/kg (range 54–1268), 



























Fig. 1  Evaluation of immune checkpoint inhibitor-induced entero-
colitis using endoscopic scores developed for Crohn’s disease and 
ulcerative colitis. a Colonoscopy findings were categorized based on 
global endoscopic assessment (GEA) of the most inflamed segment 
(normal, mild, moderate, or severe inflammation), and compared to 
endoscopic index scores generated using the Ulcerative Colitis Endo-
scopic Index of Severity (UCEIS; 0–8 points) [25], Simple Endo-
scopic Score for Crohn’s Disease (SES-CD; 0–12 points) [26], and a 
combined endoscopic score (sum of individual UCEIS and SES-CD 
scores; 0–20 points). b Colonic mucosal histopathology was catego-
rized into normal, mild, moderate, or severe inflammation, and com-
pared to the combined endoscopic score. Columns and error bars rep-












































Fig. 2  Laboratory inflammatory biomarkers in patients with immune 
checkpoint inhibitor-induced enterocolitis, in relation to corticoster-
oid and vedolizumab treatment. a Plasma albumin concentrations at 
enterocolitis onset, during corticosteroid therapy just before starting 
vedolizumab, and after vedolizumab therapy. b Plasma C-reactive 
protein concentrations at corresponding time-points. c Fecal calpro-
tectin concentrations at corresponding time-points. Enterocolitis 
onset: at onset of ICPI-induced enterocolitis, Corticosteroid therapy: 
just prior to initiation of vedolizumab treatment, Post vedolizumab: 
after vedolizumab treatment and after corticosteroids had been 
tapered. P plasma, F fecal, CRP C-reactive protein, ICPI immune 
checkpoint inhibitor. Individual values and medians; *P < 0.05 (Wil-
coxon test); n = 6 (patient No. 3, who received vedolizumab prophy-
lactically, was excluded from this analysis)
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levels of P-CRP and F-calprotectin decreased even further 
to 6.5 mg/L (range 0.3–16.0) and 76 mg/kg (range 15–199) 
(Fig.  2b, c). In contrast, P-albumin levels decreased after 
treatment with corticosteroids (median 30  g/L; range 
23–39) and increased after administration of vedolizumab 
(median 37 g/L; range 27–40) (Fig. 2a).
Examination of blood lymphocyte levels and the neutro-
phil/lymphocyte ratio (NLR) showed decreased levels of 
lymphocytes and an increase in the NLR after patients had 
been treated with corticosteroids (Fig. 3b, c). After vedoli-
zumab therapy, these parameters were normalized (Fig. 3b, 
c).
Discussion
We report on our experience of vedolizumab as an effec-
tive and safe therapy for treating ICPI-induced enterocol-
itis in selected patients, based on a case series of seven 
patients. These results corroborate a recent report on a 
single patient who had developed colitis secondary to ipili-
mumab therapy and was successfully treated with vedoli-
zumab [29]. The patients selected for vedolizumab therapy 
in our retrospective study were either steroid-dependent 
and/or partially steroid refractory. Management in accord-
ance with established algorithms with corticosteroids was 
applied but tapering was not feasible in these patients [5]. 
Additional immunosuppressive therapy was required to 
control the enterocolitis, and these patients thus represent a 
group of difficult-to-treat cases. This is underscored by the 
fact that the patients were on futile corticosteroid therapy 
for a median of 79 days before vedolizumab therapy was 
started. However, since all patients were on corticosteroids 
when vedolizumab therapy was initiated, the gut inflamma-
tion and symptoms were generally mild to moderate at this 
point. We considered the most adequate read-out parame-
ter with regards to vedolizumab efficacy to be steroid-free 
enterocolitis remission. Our findings suggest that admin-
istration of two to four infusions of vedolizumab is suffi-
cient to achieve steroid-free remission. In our patients, this 
endpoint was reached within a median of 56 days from the 
start of vedolizumab treatment. This may be compared to 
recommendations advocating the use of infliximab together 
with a steroid-taper over 45–60 days or more in cases of 
steroid refractory ICPI-induced enterocolitis [4]. Consid-
ering the exhaustive attempts to control the inflammation 
with corticosteroids including high doses and repeated 
unsuccessful tapering, it is very unlikely that the inflamma-
tion would have resolved without additional immunosup-
pressive therapy. Vedolizumab was chosen for this purpose 
as infliximab was considered excessive in relation to irAE 
severity; moreover, there is an unclear relationship between 














































Fig. 3  Blood lymphocyte and neutrophil counts in patients with 
immune checkpoint inhibitor-induced enterocolitis, in relation to 
ICPI, corticosteroid, and vedolizumab treatment. a Blood neutro-
phil counts before onset of enterocolitis, at enterocolitis onset, dur-
ing corticosteroid therapy just before starting vedolizumab, and after 
vedolizumab therapy. b Blood lymphocyte counts at corresponding 
time-points. c The blood neutrophil/lymphocyte ratio at correspond-
ing time-points. Individual values and medians. Blood cell counts 
were not available in all patients. Pre ICPI: just prior to initiation of 
ICPI therapy, Enterocolitis onset: at onset of ICPI-induced entero-
colitis, Corticosteroid therapy: just prior to initiation of vedolizumab 
treatment, Post vedolizumab: after vedolizumab treatment and after 
corticosteroids had been tapered. B blood, ICPI immune checkpoint 
inhibitor, NLR neutrophil/lymphocyte ratio
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The diagnosis of ICPI-induced enterocolitis was con-
firmed endoscopically and histopathologically in all 
patients. It is well known that the correlation between the 
degree of gastrointestinal symptoms and the level of gut 
inflammation is often poor. Therefore, gastroenterologists 
aim at using structured and objective measures of inflam-
mation for evaluation and monitoring of inflammatory gut 
disorders. Since ICPI-induced enterocolitis may exhibit 
features typical for both Crohn’s disease and/or ulcera-
tive colitis, we combined two validated scores for Crohn’s 
disease (SES-CD) and ulcerative colitis (UCEIS), respec-
tively, when evaluating enterocolitis in these patients. Inter-
estingly, the combined score corresponded better to the 
histopathological degree of inflammation (Fig.  1b), than 
the global endoscopic assessment did (data not shown), 
suggesting that development of a specific endoscopic index 
for ICPI-induced enterocolitis would be useful for a more 
accurate grading of the inflammation. This, in turn, would 
be helpful in choosing and evaluating appropriate anti-
inflammatory therapies.
In addition to enabling corticosteroid tapering, vedoli-
zumab treatment led to a notable reduction in the levels of 
F-calprotectin and P-CRP, reflecting the attenuated inflam-
mation in the gut. This was supported by a normalizing 
trend in P-albumin. The changes observed in blood cell 
counts were expected, given known effects of corticoster-
oids causing lymphopenia and neutrophilia [14].
There were no vedolizumab-related adverse events 
among our patients, which is in agreement with the docu-
mented favorable safety profile of vedolizumab. Results 
from six clinical trials for IBD comprising 2830 patients 
and 4811 person-years of vedolizumab exposure have not 
shown any increased risks of infections, serious infections 
including PML, malignancies, or infusion-related reactions 
over placebo [16, 17, 21]. Among the various immuno-
suppressants, systemic corticosteroids show the strongest 
association with serious infections, but the risk increases 
steeply when systemically immunsuppressive agents are 
combined [34–37]. It seems that serious infections in the 
context of infliximab therapy for irAEs are relatively rare, 
but nevertheless potentially fatal. There are case reports on 
the subject [38–40], and a retrospective study of 740 ICPI-
treated patients with melanoma found the rate of serious 
infections to be 7.3% and identified corticosteroids and/or 
infliximab as the main risk factors [37].
Treatment with infliximab is recommended in cases 
of corticosteroid refractory ICPI-induced enterocolitis 
[4, 41, 42]. In a recent study on 254 melanoma patients 
with irAEs, 29 (11.4%) patients received infliximab ther-
apy and high-dose corticosteroids [43]. Among these 
29 patients, 21 patients responded to infliximab but 8 
(27.6%) did not respond and received prolonged courses 
of corticosteroids. There is very little data available on 
the effects and safety of infliximab treatment in this 
context and on the potential effects of corticosteroids 
in combination with infliximab on the anti-tumor effi-
cacy of ICPI therapy [42]. In a retrospective study on 
ipilimumab-treated melanoma patients who had devel-
oped diarrhea, there was no significant difference in the 
median overall survival time between those treated with 
infliximab (n = 7) and those treated with corticosteroids 
only (n = 29) [44]. However, an important aspect omitted 
in this type of analysis is that the median overall survival 
time of the infliximab-treated patient group could have 
been even longer had they not received infliximab. This 
question could be addressed in studies utilizing vedoli-
zumab. There is an ongoing debate whether irAEs and/
or the severity of irAEs is associated with better cancer-
specific outcomes, and whether treatment with immuno-
suppressive agents potentially counteracts the anti-tumor 
effect of ICPI therapy. There are several studies support-
ing these concepts [3, 44–49] but also those refuting 
them [5, 43, 44, 48, 50–52].
We believe that vedolizumab is an appropriate choice 
of therapy for many but not all patients with ICPI-induced 
enterocolitis. For instance, patients with extraintestinal 
irAEs may require systemic immunosuppression rather 
than vedolizumab which has a gut-specific effect. In our 
material, only one out of seven patients (14%) had addi-
tional irAEs, and in a larger published cohort, this pro-
portion was 37% [53]. As illustrated by patient No. 7, 
vedolizumab may also be used as second-line therapy in 
infliximab-refractory cases, which is true in IBD as well 
[22]. In addition, vedolizumab may be considered when 
contraindications to infliximab prevail or when inflixi-
mab is not tolerated. In one of the patients, vedolizumab 
was administered prophylactically to prevent a flare of 
preexisting and mildly active UC. Unfortunately, this 
was not successful; this could speak against vedolizumab 
being efficacious in this type of scenario. But given that 
this was a single case, the concept of prophylactic ved-
olizumab therapy in patients with known IBD should be 
explored in larger studies. Interestingly, there are reports 
on patients with IBD who received ipilimumab without 
increased disease activity [54]. Other situations where 
prophylactic treatment with vedolizumab could be sug-
gested are (a) combination treatment with ipilimumab and 
a PD-1 inhibitor where the risk of severe enterocolitis is 
increased [3], and (b) adjuvant ICPI therapy in high-risk 
resected melanoma where the acceptance for irAEs may 
be decreased given an apparent lack of malignant disease 
[9]. Taken together, patients that we consider suitable for 
vedolizumab treatment are those with steroid-dependent 
and/or partially refractory mild to moderate enterocolitis, 
and without extraintestinal irAEs that require additional 
immunosuppression. In contrast, patients with severe gut 
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inflammation that demands urgent measures should be 
considered for other therapies such as infliximab or, as 
last resort, colectomy.
In conclusion, this is the first case series to suggest that 
vedolizumab is an effective and well-tolerated therapy for 
steroid refractory and/or dependent enterocolitis caused 
by treatment with ipilimumab or nivolumab. In addition 
to these, and pembrolizumab, there are several new ICPI 
agents being subjected to clinical evaluation in numer-
ous types of malignancies, and subsequently the preva-
lence of ICPI-induced enterocolitis may be expected to 
increase considerably in the near future. Thus, there is a 
growing need for developing evidence-based and increas-
ingly optimized irAE management algorithms, taking the 
long-term cancer-treatment strategy and the overall sur-
vival into account.
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